Welcome to our dedicated page for LifeStance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
BlackRock, Inc. reported a significant ownership position in Lifestance Health Group Inc. common stock on a Schedule 13G. BlackRock beneficially owns 32,034,464 shares, representing 8.3% of Lifestance’s outstanding common stock. These shares are held by certain BlackRock business units.
BlackRock has sole voting power over 31,739,667 shares and sole dispositive power over all 32,034,464 shares, with no shared voting or dispositive power reported. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Lifestance’s outstanding common shares.
LifeStance Health Group, Inc. director Kenneth A. Burdick reported an equity award under which he acquired 45,495 shares of common stock at $0.0000 per share, characterized as a grant or award acquisition. Following this award, he reports 3,470,810 shares held directly and 46,511 shares held indirectly through Burdick Family LLC. His reported holdings include 45,495 restricted stock units, each representing a contingent right to receive one share of common stock.
Palmer Eric P reported acquisition or exercise transactions in this Form 4 filing.
LifeStance Health Group, Inc. director Eric P. Palmer received an equity award of 17,746 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and increases his directly held position to 89,174 shares, including these RSUs, which each represent a contingent right to one share of common stock.
Bessler Robert reported acquisition or exercise transactions in this Form 4 filing.
LifeStance Health Group director Robert Bessler reported a new equity award and updated holdings. He received 17,746 restricted stock units, each representing one share of common stock, at a price of $0.00 per share, increasing his direct holdings to 75,365 common shares, including these RSUs.
He also reports indirect ownership positions in several entities: 36,363 common shares held by Alpine Glow Capital, 656,560 common shares held by Shama LLC, and 539,763 common shares held by Vitthal LLC. In each case, he disclaims beneficial ownership beyond his pecuniary interest.
LifeStance Health Group, Inc. director Sarah Personette received an equity grant of common stock. She acquired 17,746 shares at a stated price of $0.00 per share as a grant, increasing her direct holdings to 92,512 shares of common stock.
The grant includes 17,746 restricted stock units (RSUs), and each RSU represents a contingent right to receive one share of LifeStance common stock. This is a compensation-related award rather than an open-market purchase.
LifeStance Health Group director Teresa DeLuca received an equity grant. She acquired 17,746 shares of common stock in the form of restricted stock units (RSUs), which are rights to receive one share of common stock per unit at no cash cost. After this award, she directly holds 125,034 shares of the company’s common stock, indicating a larger equity stake aligned with shareholder interests through stock-based compensation rather than open-market purchases or sales.
LifeStance Health Group, Inc. director Justice Thurman reported receiving an award of 35,492 shares of common stock in the form of restricted stock units (RSUs) on July 2, 2026. The RSU grant was recorded at a price of $0.00 per share, reflecting a compensation-related acquisition rather than an open-market purchase. Following this award, Thurman directly holds 35,492 RSUs, each representing a contingent right to receive one share of LifeStance common stock.
LifeStance Health Group, Inc. director Lori Goltermann reported an equity compensation award. On July 2, 2026, she acquired 35,492 shares of common stock at $0.00 per share through a grant classified as restricted stock units (RSUs). Following this award, she directly holds 35,492 shares, all represented by RSUs, each of which entitles her to receive one share of LifeStance common stock if vesting conditions are met.
LifeStance Health Group, Inc. director Lori Goltermann has filed an initial Form 3, which is a statement of beneficial ownership for new insiders. This filing establishes her status as a reporting person but does not report any share purchases, sales, or other transactions.
LifeStance Health Group, Inc. director Justice Thurman has filed an initial Form 3 ownership report. The filing does not list any buy, sell, or other insider transactions or derivative positions, indicating that this is a baseline disclosure of status as a reporting person rather than a trading event.